Management of a Rapidly Progressing Huge Pancreatic Pseudocyst.

Cureus

Internal Medicine, Catholic Health, Buffalo, USA.

Published: February 2025

Pancreatic pseudocysts are a complication of both acute and chronic pancreatitis that usually develop four to six weeks from the onset of pancreatitis. Alcoholic pancreatitis is the most important risk factor for developing such cysts, although non-alcoholic cases do also occur. This is the case of a 58-year-old male patient who presented to our emergency department with a two-day history of abdominal pain, nausea, vomiting, and inability to tolerate oral food and liquids. His initial labs showed significantly elevated lipase and triglycerides. A computed tomography (CT) scan showed extensive, ill-defined pancreatic enlargement with inflammatory changes consistent with severe acute pancreatitis. Following his hospital course, on day 15, a CT abdomen/pelvis with contrast showed a new, huge pseudocyst anteriorly from the pancreas measuring 9.5 × 18 × 15 cm that rapidly progressed to 25.5 × 17.7 × 22 cm in a week with a significant mass effect. No previous sign of pseudocyst existed before this time, indicating rapid progression. Drainage and subsequent necrosectomy with stent placement were subsequently performed. To the best of our knowledge, this is the first instance of such a rapid progression of pancreatitis to large pseudocyst formation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896006PMC
http://dx.doi.org/10.7759/cureus.78768DOI Listing

Publication Analysis

Top Keywords

rapid progression
8
management rapidly
4
rapidly progressing
4
progressing huge
4
huge pancreatic
4
pseudocyst
4
pancreatic pseudocyst
4
pseudocyst pancreatic
4
pancreatic pseudocysts
4
pseudocysts complication of
4

Similar Publications

SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS inhibitor in KRAS LUAD.

Proc Natl Acad Sci U S A

March 2025

Laboratorio 1. Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas-Universidad de Salamanca and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Salamanca 37007, Spain.

We evaluated the in vivo therapeutic efficacy and tolerability of BI-3406-mediated pharmacological inhibition of SOS1 in comparison to genetic ablation of this universal Ras-GEF in various KRAS-dependent experimental tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2 mice, SOS1 pharmacological inhibition by its specific inhibitor BI-3406 did not significantly affect animal weight/viability nor cause noteworthy systemic toxicity. Allograft assays using different KRAS cell lines showed that treatment with BI-3406 impaired RAS activation and RAS downstream signaling and decreased tumor burden and disease progression as a result of both tumor-intrinsic and -extrinsic therapeutic effects of the drug.

View Article and Find Full Text PDF

Semiconductor devices often rely on high-purity materials and interfaces achieved through vapor- and vacuum-based fabrication methods, which can enable precise compositional control down to single atomic layers. Compared to groups IV and III-V semiconductors, hybrid perovskites (HPs) are an emergent class of semiconductor materials with remarkable solution processability and compositional variability that have facilitated rapid experimentation to achieve new properties and progress toward efficient devices, particularly for solar cells. Surprisingly, vapor deposition techniques for HPs are substantially less developed, despite the complementary benefits that have secured vapor methods as workhorse tools for semiconductor fabrication.

View Article and Find Full Text PDF

Decoding Microglial Polarization and Metabolic Reprogramming in Neurodegenerative Diseases: Implications for Disease Progression and Therapy.

Aging Dis

February 2025

Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China.

As the resident macrophages of the brain, microglia are crucial immune cells specific to the central nervous system (CNS). They constantly surveil their surroundings and trigger immunological reactions, playing a key role in various neurodegenerative diseases (ND). As illnesses progress, microglia exhibit multiple phenotypes.

View Article and Find Full Text PDF

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Cells

March 2025

SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP) Pan African Research Institute (PACRI), University of Pretoria, Hartfield, Pretoria 0028, South Africa.

The peremptory need to circumvent challenges associated with poorly differentiated epithelial endometrial cancers (PDEECs), also known as Type II endometrial cancers (ECs), has prompted therapeutic interrogation of the prototypically intractable and most prevalent gynecological malignancy. PDEECs account for most endometrial cancer-related mortalities due to their aggressive nature, late-stage detection, and poor response to standard therapies. PDEECs are characterized by heterogeneous histopathological features and distinct molecular profiles, and they pose significant clinical challenges due to their propensity for rapid progression.

View Article and Find Full Text PDF

Sepsis is a complex clinical syndrome closely associated with the occurrence of acute organ dysfunction and is often characterized by high mortality. Due to the rapid progression of sepsis, early diagnosis and intervention are crucial. Recent research has focused on exploring the pathological response involved in the process of sepsis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!